Comparative Pharmacology
Head-to-head clinical analysis: NATACYN versus VFEND.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NATACYN versus VFEND.
NATACYN vs VFEND
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Natamycin is a polyene antifungal that binds to ergosterol in fungal cell membranes, increasing permeability and causing cell death.
Inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
One drop of 5% ophthalmic suspension into the conjunctival sac every 1-2 hours for 48 hours, then taper to one drop 4-6 times daily.
IV: Loading dose of 6 mg/kg every 12 hours for 2 doses, then 4 mg/kg every 12 hours. Oral: Weight ≥40 kg: Loading dose of 400 mg every 12 hours for 2 doses, then 200 mg every 12 hours; weight <40 kg: Loading dose of 200 mg every 12 hours for 2 doses, then 100 mg every 12 hours.
None Documented
None Documented
Not well characterized due to minimal systemic absorption; estimated to be 2-3 hours in plasma if absorbed.
Terminal half-life is approximately 24 hours (range 12–30 h) in adults. Prolonged in hepatic impairment (Child-Pugh A: 48 h; B: 72 h).
Primarily fecal via biliary elimination; less than 5% renal excretion of absorbed dose.
Primarily hepatic metabolism; <2% excreted unchanged in urine. Fecal excretion accounts for ~80% of metabolites. Renal excretion of unchanged drug is negligible.
Category C
Category C
Antifungal, Ophthalmic
Antifungal